Simulated regional mean wetland seasons. حسب Nic Gedney (19762301)

Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. حسب Nic Gedney (19762301)

Changes in decadal precipitation and JULES inundation between 1990–1999 and 2089–2098. حسب Nic Gedney (19762301)

Contemporary mean inundation fraction in the Amazon basin. حسب Nic Gedney (19762301)

Autaptic neurotransmission accounts for a large fraction of the total inhibition onto single PV cells. حسب Charlotte Deleuze (501971)

Transformation of impulse responses by depolarization in <i>C</i>. <i>vicina</i> model. حسب Roman V. Frolov (9647905)

Deletion of <i>Hmr’s</i> C-terminus results in failure to rescue hybrid lethality. حسب Andrea Lukacs (3752956)

Data_Sheet_1_Specific Integration of Temperate Phage Decreases the Pathogenicity of Host Bacteria.docx حسب Yibao Chen (5517782)

"…However, little is known about the roles of temperate phages in attenuation of bacterial virulence. Here, we report a novel Bordetella bronchiseptica temperate phage, vB_BbrS_PHB09 (PHB09), which has a 42,129-bp dsDNA genome with a G+C content of 62.8%. …"

Association of SDOH scores with attitudes, practices and mental health outcomes among Arkansans overall and by race and ethnicity ^a^,^b^,<s... حسب Jenil R. Patel (3639451)

Temporal trends in large carnivore attacks on humans in different regions of the world. حسب Giulia Bombieri (8613945)

"…In countries with (<b>D</b>) large forest coverage, the number of attacks in the last several years has decreased. …"

Near-Infrared-Absorbing B–N Lewis Pair-Functionalized Anthracenes: Electronic Structure Tuning, Conformational Isomerism, and Applications in Photothermal Cancer Therapy حسب Kanglei Liu (1992742)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)